Abstract

Coagulation Factor VIII is activated by an ordered limited thrombin proteolysis with different catalytic efficiency at three P1 Arginine residues: Arg759> Arg1708>Arg391, indicating the flanking residues of the latter to be less optimal. This study aimed to investigate, in silico and in vitro, the impact of possessing hypothetically optimized residues at these three catalytic cleavage sites. The structural impact of the residues flanking Arginine cleavage sites was studied by in silico analysis through comparing the cleavage cleft of the native site with a hypothetically optimized sequence at each site. Moreover, recombinant FVIII proteins were prepared by replacing the sequences flanking native thrombin cleavage sites with the proposed cleavage-optimized sequence. FVIII specific activity was determined by assessing the FVIII activity levels in relation to FVIII antigen levels. We further investigated whether thrombin generation could reflect the haemostatic potential of the variants. Our in silico results show the impact of the residues directly in the cleavage bond, and their neighboring residues on the insertion efficiency of the loop into the thrombin cleavage cleft. Moreover, the in vitro analysis shows that the sequences flanking the Arg1708 cleavage site seem to be the most close to optimal residues for achieving the maximal proteolytic activation and profactor activity of FVIII. The residues flanking the scissile bonds of FVIIII affect the cleavage rates and modulate the profactor activation. We were able to provide insights into the mechanisms of the specificity of thrombin for the P1 cleavage sites of FVIII. Thus, the P4-P2´ residues surrounding Arg1708 of FVIII have the highest impact on rates of thrombin proteolysis which contributes to thrombin activation of the profactor and eventually to the thrombin generation potential.

Highlights

  • Blood clotting factor VIII (FVIII) is a nonenzymatic cofactor of activated factor IX (FIXa)

  • To generate the final holoenzyme complex, the factor XIII-(28–37) decapeptide was replaced with FVIII amino acids (18 residues in total) of the three thrombin cleavage site peptide models, one at a time starting with the P1 Arginine residue generating an inserted thrombin cleavage site peptide with the scissile bond in the approximate middle and in enzymatic proximity to the nucleophilic Ser195 residue of thrombin

  • The Arg391 cleavage site peptide structure shows a number of Lysines close to the scissile bond resulting in an electrostatic positive center that is stabilized by Aspartic acid and Glutamine residues close to the Ser195 (Fig 2A)

Read more

Summary

Introduction

Blood clotting factor VIII (FVIII) is a nonenzymatic cofactor of activated factor IX (FIXa). Modification of FVIII thrombin cleavage sites the tenase complex [1]. The FVIII protein is synthesized as a ~330 kDa single-chain molecule with six distinct domains. It consists of three homologous A-domains, a unique B-domain and two C-domains [2]. Due to cleavage at the Ba3 junction, followed by a number of additional cleavages within the B domain, a variably sized heavy chain (A1-a1-A2-a2-B) and a light chain (a3-A3-C1-C2) are generated [3]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call